On June 29, China Intellectual Property Society(CIPS) released the 2022 Investigation Report on IP Disputes of Chinese Enterprises in the US. According to the report, a total of 986 new intellectual property lawsuits of Chinese enterprises were filed in the US in 2022, up 14.39%.
On Jun 28, Huawei announced on its official website that it has entered into a patent license agreement with Quality Tech S.R.L. The agreement grants a license on Huawei's patents relating to Optical Distribution Network (ODN) products to Quality Tech and its customers.
Leading lithium-ion batteries supplier Amperex Technology Limited (ATL) has filed two separate patent lawsuits against its rival COSMX, according to announcements released within less than a week by COSMX. ATL is seeking a total of over 128 million yuan for compensation.
On June 25, the China National Intellectual Property Administration(CNIPA) issued a notice to increase fees in RMB for the international phase of PCT applications. According to the notice, international application documents of up to 30 pages will be charged 10350 yuan (+7.59%).
On June 15, AbbVie filed a lawsuit against BeiGene, claiming that BeiGene’s Brukinsa has infringed a patent on its blood cancer drug Imbruvica. The disputed patent, which relates to the "use of BTK inhibitors", was issued on June 13, just two days before AbbVie lodged the suit.
